Alnylam Pharmaceuticals Inc
Company Profile
Business description
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam’s commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam’s partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.
Contact
675 West Kendall Street
Henri A. Termeer Square
CambridgeMA02142
USAT: +1 617 551-8200
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
2,500
Stocks News & Analysis
stocks
Ahead of an IPO, the maths behind Databrick’s $190 billion valuation doesn’t add up
stocks
Takeover proposal agreed for ASX share, other offers permitted
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,919.10 | 3.60 | -0.04% |
| CAC 40 | 8,143.41 | 78.39 | 0.97% |
| DAX 40 | 25,586.62 | 282.56 | 1.12% |
| Dow JONES (US) | 51,682.64 | 95.40 | -0.18% |
| FTSE 100 | 10,758.47 | 99.34 | 0.93% |
| HKSE | 25,042.71 | 291.93 | 1.18% |
| NASDAQ | 26,522.54 | 104.25 | 0.39% |
| Nikkei 225 | 65,018.95 | 882.70 | 1.38% |
| NZX 50 Index | 13,821.20 | 82.06 | 0.60% |
| S&P 500 | 7,650.50 | 12.74 | 0.17% |
| S&P/ASX 200 | 8,731.90 | 0.70 | 0.01% |
| SSE Composite Index | 3,949.91 | 38.04 | 0.97% |